Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
Open Access
- 1 January 2014
- journal article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 5 (5) , 320-327
Abstract
Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease.Keywords
This publication has 36 references indexed in Scilit:
- Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for cliniciansTherapeutic Advances in Medical Oncology, 2013
- Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathyBreast Cancer Research and Treatment, 2013
- Treating Breast Cancer in the 21st Century: Emerging Biological TherapiesJournal of Cancer, 2013
- Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectivesCritical Reviews in Oncology/Hematology, 2011
- The Place for Eribulin in the Treatment of Metastatic Breast CancerCurrent Oncology Reports, 2010
- Metastatic Breast Cancer: Overall Survival Related to Successive Chemotherapies. What Do We Gain After the Third Line?Cancer Investigation, 2009
- Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast CancerJournal of Clinical Oncology, 2008
- Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast CancerJournal of Clinical Oncology, 2007
- Capecitabine Monotherapy: Safe and Effective Treatment for Metastatic Breast CancerThe Oncologist, 2006